RESUMEN
A series of 3-substituted 2-pyridinyl-1-piperazine derivatives have been appended to cyclic imide groups and evaluated for their potential antipsychotic activity. The dopamine receptor affinities of these target molecules, as well as their ability to block apomorphine-induced stereotypy or reverse neuroleptic-induced catalepsy, was dependent on the lipophilic and electronic characteristics of the substituent situated on the pyridine ring. Groups with + omega and - phi values were most consistent with the desired biological profile of the target molecules, the cyano moiety being the optimum choice. Evaluation of compound 12 in a monkey model of amphetamine psychosis, and the regional selectivity it expresses for the A10 dopaminergic cell bodies in electrophysiological experiments, suggest this compound would be an atypical antipsychotic agent with few side effects.
Asunto(s)
Antipsicóticos/síntesis química , Piperazinas/síntesis química , Animales , Apomorfina/antagonistas & inhibidores , Catalepsia/inducido químicamente , Dioxanos/farmacología , Electrofisiología , Haplorrinos , Piperazinas/farmacología , Ratas , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacología , Conducta Estereotipada/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
Several analogues of the novel anxiolytic buspirone were synthesized and evaluated in vivo for tranquilizing activity and their ability to reverse neuroleptic-induced catalepsy. The in vitro binding affinities of these compounds were also examined for both the alpha 1 and dopamine D2 receptor systems. The general structure-activity relationships of this series highlight compounds 17, 21, and 32 as having anticonflict activity. Each of these structures contains the 1-(2-pyrimidinyl)piperazine moiety linked by a tetramethylene chain to a variable cyclic imide moiety. Compound 32 (4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6- piperidinedione) was found to be equipotent with buspirone in its anxiolytic activity and was therefore selected for extensive preclinical characterization. The pharmacology of buspirone and 32 is contrasted, and the potent serotonin agonist properties of 32 are discussed with reference to its potential contribution to the anxioselective mechanism of this compound.
Asunto(s)
Ansiolíticos/síntesis química , Pirimidinas/síntesis química , Ácido 3,4-Dihidroxifenilacético/metabolismo , Antagonistas Adrenérgicos alfa/síntesis química , Antagonistas Adrenérgicos alfa/farmacología , Animales , Ansiolíticos/farmacología , Buspirona , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Ácido Homovanílico/metabolismo , Espectroscopía de Resonancia Magnética , Masculino , Metoxihidroxifenilglicol/metabolismo , Ratones , Pirimidinas/farmacología , Ratas , Ratas Endogámicas , Relación Estructura-ActividadRESUMEN
The literature describing the role of serotonin (5-HT) in the mediation of anxiety is a controversial one. Serotonergic involvement in the mechanism of action of two nonbenzodiazepine anxiolytics, buspirone and gepirone, supports a role for serotonin in anxiety. The anticonflict effect of both drugs is blocked by serotonin lesions, and gepirone induces the serotonin syndrome. A shift in the gepirone dose-response curve to the left in serotonin lesioned rats suggests that this may be 5-HT-receptor mediated. Both buspirone and gepirone enhance the acoustic startle response and gepirone's effect is attenuated in serotonin lesioned animals. While other components of buspirone's mechanism of action may suppress the behavioral expression of its serotonergic interactions, results from these studies suggest that serotonin agonist-like activity may be an important mechanism in the actions of a clinically proven nonbenzodiazepine anxiolytic (buspirone), and anxiolytic candidate (gepirone).
Asunto(s)
Ansiolíticos/farmacología , Conducta Animal/efectos de los fármacos , Pirimidinas/farmacología , Serotonina/fisiología , 5,7-Dihidroxitriptamina/farmacología , Animales , Aminas Biogénicas/metabolismo , Buspirona , Conflicto Psicológico , Diazepam/farmacología , Masculino , Ratas , Ratas Endogámicas , Reflejo de Sobresalto/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacosRESUMEN
Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.
Asunto(s)
Antipsicóticos/síntesis química , Isoxazoles/síntesis química , Oxazoles/síntesis química , Piperazinas/síntesis química , Tiazoles/síntesis química , Animales , Reacción de Prevención/efectos de los fármacos , Unión Competitiva , Catalepsia/inducido químicamente , Corteza Cerebral/metabolismo , Cuerpo Estriado/metabolismo , Isoxazoles/farmacología , Masculino , Modelos Moleculares , Norepinefrina/antagonistas & inhibidores , Fisostigmina/antagonistas & inhibidores , Piperazinas/farmacología , Ratas , Ratas Endogámicas , Receptores Adrenérgicos alfa/metabolismo , Receptores Dopaminérgicos/metabolismo , Receptores de Dopamina D2 , Receptores de Serotonina/efectos de los fármacos , Sueño/efectos de los fármacos , Compuestos de Espiro/farmacología , Conducta Estereotipada/efectos de los fármacos , Relación Estructura-Actividad , Tiazoles/farmacologíaRESUMEN
Clinical trials have demonstrated that buspirone (BuSpar) is effective in the treatment of anxiety with efficacy and dosage comparable to diazepam or chlorazepate. Buspirone has a unique structure and a pharmacologic profile which distinguishes it from the benzodiazepines. Because it lacks the anticonvulsant, sedative, and muscle-relaxant properties associated with other anxiolytics, buspirone has been termed "anxioselective." Animal studies suggest that it lacks potential for abuse, and this finding is supported by clinical investigations. Further preclinical work supports the contention that buspirone lacks liability to produce physical dependence or to significantly interact with central nervous system depressants such as ethanol. Moreover, biochemical investigations have not identified any direct interaction of buspirone with the benzodiazepine-gamma-aminobutyric acid-chloride ionophore complex. Pharmacologic studies on the molecular level indicate that buspirone interacts with dopamine and serotonin receptors. Recent behavioral, electrophysiological, and biochemical studies have clearly demonstrated that early hypotheses that buspirone might be considered a neuroleptic are no longer tenable. Recent evidence indicates that other neurotransmitter systems (serotonin, norepinephrine, acetylcholine) mediate buspirone's effects. It is hoped that future studies can define the mechanism by which buspirone alleviates the clinical manifestations of anxiety.
Asunto(s)
Ansiolíticos/farmacología , Pirimidinas/farmacología , Animales , Ansiolíticos/metabolismo , Ansiolíticos/uso terapéutico , Anticonvulsivantes/farmacología , Antipsicóticos/farmacología , Autorradiografía , Encéfalo/metabolismo , Buspirona , Depresores del Sistema Nervioso Central/farmacología , Conflicto Psicológico/efectos de los fármacos , Interacciones Farmacológicas , Humanos , Ratones , Modelos Biológicos , Relajantes Musculares Centrales , Pirimidinas/metabolismo , Pirimidinas/uso terapéutico , Ratas , Reflejo/efectos de los fármacos , Trastornos Relacionados con SustanciasRESUMEN
The ability of drugs to block dopamine-agonist induced stereotypy in animals has proven to be a reliable in vivo predictor of antipsychotic efficacy in man. Assessment of a drug's potency at displacing [3H]spiperone from rat striatal membranes is an in vitro test which also has predictive validity for antipsychotic actions. Methods are described for assessing stereotyped behavior in the dog, and for measuring the ability of serum samples taken from treated animals at behaviorally interesting time points, to displace [3H]spiperone from washed synaptic membranes of rat striata. In these studies, oral administration of the potential antipsychotic agent MJ 13859-1 blocked amphetamine-induced stereotyped behavior in the dog for 6 hours. This behavioral effect was accompanied by sustained serum levels of [3H]spiperone displacing moieties derived from MJ 13859-1.
Asunto(s)
Anfetamina/antagonistas & inhibidores , Psicotrópicos/sangre , Compuestos de Espiro/sangre , Conducta Estereotipada/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Unión Competitiva , Cuerpo Estriado/metabolismo , Perros , Humanos , Técnicas In Vitro , Masculino , Psicotrópicos/farmacología , Ensayo de Unión Radioligante , Ratas , Espiperona/metabolismo , Compuestos de Espiro/farmacologíaRESUMEN
Buspirone is a clinically effective anxiolytic with a unique structure and pharmacology which distinguishes it from the benzodiazepines. It has been termed anxioselective because it lacks anticonvulsant, sedative, or muscle-relaxant properties. Preclinical evidence suggests it lacks potential for abuse or physical dependence and interacts minimally with CNS depressants such as alcohol. Rather than working through traditional benzodiazepine mechanisms, buspirone affects diverse aspects of the brain's neurochemical circuitry. For example, it exerts potent influences on the nigrostriatal and mesolimbic dopamine systems, the dorsal raphe serotonergic system, and the locus coeruleus noradrenergic system. Although without direct receptor interaction, potentiation of cholinergically mediated behavior and involvement with GABAergic neurotransmission have also been demonstrated.
Asunto(s)
Ansiolíticos/uso terapéutico , Sistema Nervioso/metabolismo , Pirimidinas/uso terapéutico , Animales , Anticonvulsivantes/uso terapéutico , Benzodiazepinas/metabolismo , Fenómenos Biomecánicos , Buspirona , Fenómenos Químicos , Química , Dopamina/metabolismo , Humanos , Hipnóticos y Sedantes/uso terapéutico , Macaca mulatta , Relajación Muscular , Músculos/efectos de los fármacos , Neuroquímica , Ratas , Trastornos Relacionados con Sustancias , Ácido gamma-Aminobutírico/metabolismoRESUMEN
A series of analogues of buspirone was synthesized in which modifications were made in the aryl moiety, alkylene chain length, and cyclic imide portion of the molecule. These compounds were tested in vitro for their binding affinities to rat brain membrane sites labeled by either the dopamine antagonist [3H]spiperone or the alpha 1-adrenergic antagonist [3H]WB-4101. Compounds were also tested in vivo for tranquilizing properties and induction of catalepsy. Potency at the [3H]spiperone binding site was affected by alkylene chain length and imide portion composition. Nonortho substituents on the aryl moiety had little effect on [3H]spiperone binding affinity. Structure-activity relationships of ortho substituents demonstrated only modest correlations between the receptor binding data and physical parameters of the substituents. The complex nature of the drug-receptor interactions may be understood in terms of the fit of buspirone to a hypothetical model of the dopamine receptor.
Asunto(s)
Ansiolíticos/síntesis química , Piperazinas/síntesis química , Pirimidinas/farmacología , Receptores Dopaminérgicos/metabolismo , Animales , Unión Competitiva , Buspirona , Cuerpo Estriado/metabolismo , Cinética , Masculino , Modelos Moleculares , Conformación Molecular , Piperazinas/farmacología , Ratas , Espiperona/metabolismo , Relación Estructura-ActividadRESUMEN
Buspirone HCl (Buspar) is a novel anxiolytic agent unrelated to the benzodiazepines or other psychotherapeutic agents. Animal studies support an anxioselective profile, i.e. relief of anxiety without sedation, muscle relaxation or anticonvulsant activity. Double-blind clinical studies show buspirone to be effective in the treatment of anxiety and anxiety in the presence of depression. The effects of buspirone on psychomotor function, physical dependence and abuse potential tests are similar to those seen with placebo treatments. Mechanism of action studies indicate activity in a variety of neuronal systems.
Asunto(s)
Trastornos de Ansiedad/tratamiento farmacológico , Pirimidinas/uso terapéutico , Agresión/efectos de los fármacos , Animales , Nivel de Alerta/efectos de los fármacos , Reacción de Prevención/efectos de los fármacos , Buspirona , Ensayos Clínicos como Asunto , Diazepam/uso terapéutico , Método Doble Ciego , Evaluación Preclínica de Medicamentos , Humanos , Macaca mulatta , Ratones , Destreza Motora/efectos de los fármacos , Ratas , Convulsiones/tratamiento farmacológico , AutoadministraciónRESUMEN
Biochemically, buspirone is unlike the benzodiazepines in that it neither stimulates nor inhibits 3H-benzodiazepine binding, does not affect the influence of GABA or halide anion on 3H-benzodiazepine binding, and does not interfere with GABA binding or uptake. Buspirone lacks anticonvulsant activity, interacts minimally with CNS depressants, and does not cause muscle relaxation. Its tranquilizing activity is characterized by the ability to (1) tame aggressive rhesus monkeys, (2) block conditioned avoidance responding in the rat, (3) inhibit shock-induced fighting in the mouse, and (4) attenuate shock-induced suppression of drinking in the rat. In vitro binding experiments indicate that buspirone lacks significant activity at several binding sites. It appears to interact only with the dopaminergic system and possesses properties that are similar to both dopamine agonists and dopamine antagonists.
Asunto(s)
Ansiolíticos/farmacología , Pirimidinas/farmacología , Agresión/efectos de los fármacos , Animales , Ansiolíticos/metabolismo , Reacción de Prevención/efectos de los fármacos , Buspirona , Fenómenos Químicos , Química , Antagonistas de Dopamina , Electrochoque , Humanos , Macaca mulatta , Ratones , Modelos Estructurales , Actividad Motora/efectos de los fármacos , Destreza Motora/efectos de los fármacos , Pirimidinas/metabolismo , Ratas , Receptores Dopaminérgicos/efectos de los fármacos , Receptores Dopaminérgicos/metabolismo , Receptores de Droga/efectos de los fármacos , Convulsiones/prevención & controlRESUMEN
Clinical trials have indicated that buspirone (Buspar) is effective in the treatment of anxiety with efficacy and dosage comparable to diazepam. Until recently it has been thought that antianxiety drugs must alter benzodiazepine receptor binding in vitro. However, buspirone lacks any structural similarity to te benzodiazepines and does not interact with the benzodiazepine/gamma-aminobutyric acid (GABA) axis. Specifically, buspirone neither stimulates nor inhibits [3H]benzodiazepine binding, does not affect the influence o GABA or halide anions on benzodiazepine binding, and does not interfere with GABA binding or uptake. Behavioral testing has revealed that buspirone does not produce muscle weakness, does not control seizures, does not potentiate the impairment of psychophysiological function or lethality produced by administration of CNS depressants, does not produce sedation/hypnosis and does not appear to possess any abuse potential or liability for physical dependence. Thus, buspirone has been termed an anxioselective agent. Buspirone appears to only interact with the dopaminergic system with reasonable potency and exhibits properties of both a dopamine agonist and a dopamine antagonist. This suggests that dopamine is implicated in the etiology and expression of anxiety. A discussion of this implication is presented with a review of the clinical efficacy of nonbenzodiazepine drugs, especially dopamine agonists and dopamine antagonists, in the management of anxiety. In addition, neuropharmacological studies which have investigated the role of dopamine in animal models of anxiety are considered. Finally, the multiplicity of dopamine receptors and their regional localization in the brain are considered in the formulation of an hypothesis which features a role for the dopaminergic agents in the pharmacotherapy of anxiety.
Asunto(s)
Ansiolíticos/uso terapéutico , Ansiedad , Dopamina/fisiología , Animales , Ansiolíticos/farmacología , Conducta Animal/efectos de los fármacos , Benzodiazepinas/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/fisiología , Humanos , Relación Estructura-ActividadAsunto(s)
Corteza Cerebral/metabolismo , Fenoxibenzamina/farmacología , Piperazinas/farmacología , Receptores de Serotonina/metabolismo , Trazodona/farmacología , Animales , Corteza Cerebral/efectos de los fármacos , Cinética , Masculino , Ratas , Receptores de Serotonina/efectos de los fármacos , Espiperona/metabolismoRESUMEN
The effect of trazodone, a new antidepressant agent, on uptake of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) by crude synaptosome preparations from rat hypothalamus was compared with imipramine, desipramine, and clomipramine. Trazodone was determined to be a very selective inhibitor of the 5-HT uptake mechanism with IC50 values of 5.67 X 10(-7), 3.54 X 10(-5), and 5.25 X 10(-5 M, for 5-HT, NE, and DA uptake, respectively. Clomipramine, the only other selective inhibitor of 5-HT uptake studied, had IC50 values of 7.59 X 10(-9), 1.12 X 10(-7), and 2.51 X 10(-7) M, for 5-HT, NE, and DA, respectively. Although less potent, trazodone was 4 +/- 0.6 times more selective than clomipramine in its ability to inhibit synaptosomal uptake of 5-HT with respect to NE. This selectivity for the 5-HT uptake mechanism is consistent with the clinical antidepressant efficacy of trazodone.